Oral Nicotine Pouch Marketing Features Influence on Perceptions
Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · Sep 18, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is looking at how different marketing features of oral nicotine pouches affect how people perceive these products. The goal is to understand if the way these pouches are advertised makes a difference in how they are viewed by potential users. The study is not yet recruiting participants, but when it does, it will involve both youth and adults.
To be eligible for this study, you must live in the U.S. If you are under 21, you should have never used nicotine pouches before. For adults, you need to have smoked at least 100 cigarettes in your lifetime and currently smoke some or all days, but you should not regularly use or have used nicotine pouches in the last month. Participants can expect to provide their opinions on different marketing features, which can help researchers learn more about tobacco use and product perceptions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Live in the US
- • For youth age \<21: Never used any nicotine pouch
- • For adults: Smoked greater than or equal to 100 cigarettes in during lifetime
- • For adults: Currently smoke some or all days
- • For adults: No regular use of oral nicotine pouches
- • For adults: No past 30-day pouch use
- Exclusion Criteria:
- • Do not live in the US
- • For youth age \<21: Ever used nicotine pouches
- • For youth age \<21: Greater than or equal to 100 lifetime uses of any other nicotine or tobacco product
- • For adults: Smoked \<100 cigarettes in life
- • For adults: Does not currently smoke some or all days
- • For adults: Regular use of oral nicotine pouches
- • For adults: Past 30-day pouch use
About Johns Hopkins Bloomberg School Of Public Health
The Johns Hopkins Bloomberg School of Public Health is a leading institution dedicated to advancing public health research and education. Renowned for its rigorous academic programs and commitment to improving global health outcomes, the School conducts innovative clinical trials that address pressing health challenges. With a focus on evidence-based practices, multidisciplinary collaboration, and community engagement, the Bloomberg School leverages its extensive resources and expertise to contribute to the development of effective public health interventions and policies. Through its research endeavors, the School aims to enhance population health and inform health policy both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Meghan Moran, PhD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported